Clinical Trials
6 trialsNCT02436707 2026-04-20
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT06520098 2025-10-14
Benefit VA
VA Office of Research and Development
Phase 2 Recruiting
NCT01980654 2019-04-16
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Pharmacyclics LLC.
Phase 2 Completed
NCT02272686 2018-12-05
Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01779791 2017-07-18
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
Janssen Research & Development, LLC
Phase 2 Completed
NCT01236391 2015-08-28
PCYC-1104-CA
Pharmacyclics LLC.
Phase 2 Completed